SG11201805268XA - T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex - Google Patents

T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex

Info

Publication number: SG11201805268XA
Authority: SG; Singapore
Prior art keywords: park; international; eso; oxfordshire; abingdon
Prior art date: 2015-12-22

Application number

SG11201805268XA

Other languages

English (en)

Inventor

Fiona Chester

Andrew Alexander Knox

Jonathan Patrick Lowther

Viren Vinubhai Patel

Emma Elizabeth Baston

Ruth Martinez Hague

Original Assignee

Immunocore Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-12-22

Filing date

2016-12-22

Publication date

2018-07-30

2016-12-22 Application filed by Immunocore Ltd filed Critical Immunocore Ltd

2018-07-30 Publication of SG11201805268XA publication Critical patent/SG11201805268XA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Toxicology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Mycology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Reproductive Health (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SG11201805268XA 2015-12-22 2016-12-22 T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex SG11201805268XA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB1522592.3A GB201522592D0 (en)	2015-12-22	2015-12-22	T cell receptors
PCT/GB2016/054032 WO2017109496A1 (en)	2015-12-22	2016-12-22	T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex

Publications (1)

Publication Number	Publication Date
SG11201805268XA true SG11201805268XA (en)	2018-07-30

Family

ID=55311396

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201805268XA SG11201805268XA (en)	2015-12-22	2016-12-22	T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex

Country Status (25)

Country	Link
US (1)	US11639374B2 (sr)
EP (1)	EP3394094B1 (sr)
JP (1)	JP6985274B2 (sr)
KR (1)	KR20180090374A (sr)
CN (1)	CN109476723B (sr)
AU (1)	AU2016375994B2 (sr)
BR (1)	BR112018012794A2 (sr)
CA (1)	CA3009400A1 (sr)
CY (1)	CY1125508T1 (sr)
DK (1)	DK3394094T3 (sr)
ES (1)	ES2923026T3 (sr)
GB (1)	GB201522592D0 (sr)
HR (1)	HRP20221021T1 (sr)
HU (1)	HUE059484T2 (sr)
IL (1)	IL260151A (sr)
LT (1)	LT3394094T (sr)
MX (1)	MX395153B (sr)
MY (1)	MY196179A (sr)
PL (1)	PL3394094T3 (sr)
PT (1)	PT3394094T (sr)
RS (1)	RS63501B1 (sr)
SG (1)	SG11201805268XA (sr)
SI (1)	SI3394094T1 (sr)
SM (1)	SMT202200336T1 (sr)
WO (1)	WO2017109496A1 (sr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB201522592D0 (en)	2015-12-22	2016-02-03	Immunocore Ltd	T cell receptors
GB201604458D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against cancers
JP2020503883A (ja) *	2017-01-13	2020-02-06	アジェナスインコーポレイテッド	Ｎｙ−ｅｓｏ−１に結合するｔ細胞受容体およびその使用方法
LT3428194T (lt) *	2017-07-14	2021-12-10	Immatics Biotechnologies Gmbh	Pagerinta dvejopo savitumo polipeptido molekulė
CN109837245A (zh) *	2017-11-25	2019-06-04	深圳宾德生物技术有限公司	一种tcr敲除的靶向ny-eso-1的t细胞受体基因修饰t细胞及其制备方法和应用
WO2019133443A1 (en) *	2017-12-28	2019-07-04	Janux Therapeutics, Inc.	Modified t cell receptors
TWI822726B (zh) *	2018-02-26	2023-11-21	德商梅迪基因免疫治療公司	Ｎｙｅｓｏｔ細胞受體
CA3111381A1 (en) *	2018-09-05	2020-04-30	The Regents Of The University Of California	Composition of ny-eso-1-specific t cell receptors restricted on multiple major histocompatibility complex molecules
WO2020086647A1 (en) *	2018-10-23	2020-04-30	Regeneron Pharmaceuticals, Inc.	Ny-eso-1 t cell receptors and methods of use thereof
US12139523B2 (en)	2018-11-27	2024-11-12	Duke University	Anti-LMP2 TCR-T cell therapy for the treatment of EBV-associated cancers
US20230192805A1 (en) *	2019-01-14	2023-06-22	Nanjing Legend Biotech Co., Ltd.	Chimeric receptor polypeptides and uses thereof
AU2020209991B2 (en)	2019-01-17	2024-11-14	Immunocore Limited	Formulations
GB201901306D0 (en)	2019-01-30	2019-03-20	Immunocore Ltd	Multi-domain binding molecules
GB201901305D0 (en)	2019-01-30	2019-03-20	Immunocore Ltd	Specific binding molecules
GB201902277D0 (en)	2019-02-19	2019-04-03	King S College London	Therapeutic agents
CN113906140B (zh) *	2019-03-18	2025-01-28	路德维格癌症研究院	A2/ny-eso-1特异性t细胞受体及其用途
GB201904328D0 (en) *	2019-03-28	2019-05-15	Immunocore Ltd	Specific binding molecules
WO2020263830A1 (en)	2019-06-25	2020-12-30	Gilead Sciences, Inc.	Flt3l-fc fusion proteins and methods of use
DE102019121007A1 (de)	2019-08-02	2021-02-04	Immatics Biotechnologies Gmbh	Antigenbindende Proteine, die spezifisch an MAGE-A binden
CN112300268B (zh) *	2019-08-02	2023-02-28	香雪生命科学技术（广东）有限公司	识别ny-eso-1抗原的高亲和力t细胞受体
TWI890283B (zh)	2020-02-14	2025-07-11	美商基利科學股份有限公司	結合ccr8之抗體及融合蛋白及其用途
PH12022500012A1 (en)	2020-03-30	2023-04-03	Daiichi Sankyo Co Ltd	Bispecific antibody
TW202406932A (zh)	2020-10-22	2024-02-16	美商基利科學股份有限公司	介白素2-Fc融合蛋白及使用方法
CN112239495B (zh) *	2020-10-29	2022-04-12	上海药明生物技术有限公司	稳定的tcr结构及应用
WO2022233956A1 (en)	2021-05-05	2022-11-10	Immatics Biotechnologies Gmbh	Antigen binding proteins specifically binding prame
WO2022245671A1 (en)	2021-05-18	2022-11-24	Gilead Sciences, Inc.	Methods of using flt3l-fc fusion proteins
US20250073333A1 (en) *	2021-07-19	2025-03-06	Board Of Regents, The University Of Texas System	Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
WO2023022235A1 (ja) *	2021-08-20	2023-02-23	大塚製薬株式会社	組み合わせ医薬
CN117964777A (zh) *	2021-08-26	2024-05-03	瑅安生物医药（杭州）有限公司	一种接近天然分子的多肽融合分子
AU2022375782B2 (en)	2021-10-28	2026-02-26	Gilead Sciences, Inc.	Pyridizin-3(2h)-one derivatives
JP7787991B2 (ja)	2021-10-29	2025-12-17	ギリアードサイエンシーズ，インコーポレイテッド	Ｃｄ７３化合物
US12122764B2 (en)	2021-12-22	2024-10-22	Gilead Sciences, Inc.	IKAROS zinc finger family degraders and uses thereof
KR20240123836A (ko)	2021-12-22	2024-08-14	길리애드 사이언시즈, 인코포레이티드	이카로스 아연 핑거 패밀리 분해제 및 이의 용도
TW202340168A (zh)	2022-01-28	2023-10-16	美商基利科學股份有限公司	Ｐａｒｐ７抑制劑
WO2023178181A1 (en)	2022-03-17	2023-09-21	Gilead Sciences, Inc.	Ikaros zinc finger family degraders and uses thereof
CR20240451A (es)	2022-04-21	2024-12-04	Gilead Sciences Inc	Compuestos de modulación de kras g12d
KR20250028371A (ko)	2022-07-01	2025-02-28	길리애드 사이언시즈, 인코포레이티드	Cd73 화합물
EP4573125A1 (en)	2022-08-18	2025-06-25	Immunocore Limited	Multi-domain binding molecules
IL318933A (en)	2022-08-18	2025-04-01	Immunocore Ltd	Multi-functional binding molecules
CN120077068A (zh)	2022-08-18	2025-05-30	英美偌科有限公司	多结构域结合分子
AU2023409398A1 (en)	2022-12-22	2025-06-05	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
AU2024252725A1 (en)	2023-04-11	2025-11-06	Gilead Sciences, Inc.	Kras modulating compounds
CR20250446A (es)	2023-04-21	2025-12-02	Gilead Sciences Inc	Inhibidores de prmt5 y usos de los mismos
AU2024306338A1 (en)	2023-06-30	2026-01-08	Gilead Sciences, Inc.	Kras modulating compounds
CN121620513A (zh)	2023-07-26	2026-03-06	吉利德科学公司	Parp7抑制剂
KR20260046403A (ko)	2023-07-26	2026-04-07	길리애드 사이언시즈, 인코포레이티드	Parp7 저해제
US20250101042A1 (en)	2023-09-08	2025-03-27	Gilead Sciences, Inc.	Kras g12d modulating compounds
US20250109147A1 (en)	2023-09-08	2025-04-03	Gilead Sciences, Inc.	Kras g12d modulating compounds
GB202315181D0 (en)	2023-10-03	2023-11-15	Immunocore Ltd	Peptide-HLA binding molecules
WO2025094054A1 (en)	2023-11-01	2025-05-08	Immunocore Limited	Method for purifying small multi-domain proteins
US20250154172A1 (en)	2023-11-03	2025-05-15	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
GB202320012D0 (en)	2023-12-22	2024-02-07	Immunocore Ltd	Bispecific molecules
WO2025137640A1 (en)	2023-12-22	2025-06-26	Gilead Sciences, Inc.	Azaspiro wrn inhibitors
WO2025245003A1 (en)	2024-05-21	2025-11-27	Gilead Sciences, Inc.	Prmt5 inhibitors and uses thereof
GB2641580A (en)	2024-06-07	2025-12-10	T Therapeutics Ltd	Tumour-transforming multispecific proteins
US20260098049A1 (en)	2024-08-12	2026-04-09	Gilead Sciences, Inc.	Kras modulating compounds
WO2026078231A1 (en)	2024-10-11	2026-04-16	T-Therapeutics Limited	Soluble non-aggregating immune ligand

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1259601A2 (en)	2000-02-22	2002-11-27	Ahuva Nissim	Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
IL160359A0 (en) *	2001-08-31	2004-07-25	Avidex Ltd	Soluble t cell receptor
CA2501870C (en)	2002-10-09	2013-07-02	Avidex Limited	Single chain recombinant t cell receptors
GB0226227D0 (en) *	2002-11-09	2002-12-18	Avidex Ltd	Receptors
AU2005246073B2 (en) *	2004-05-19	2010-10-28	Adaptimmune Limited	Method of improving T cell receptors
GB0411123D0 (en) *	2004-05-19	2004-06-23	Avidex Ltd	High-affinity NY-ESO T cell receptors
ATE417065T1 (de)	2004-05-19	2008-12-15	Medigene Ltd	Hochaffiner ny-eso-t-zellen-rezeptor
US8088379B2 (en)	2006-09-26	2012-01-03	The United States Of America As Represented By The Department Of Health And Human Services	Modified T cell receptors and related materials and methods
WO2008037943A1 (en) *	2006-09-29	2008-04-03	Medigene Limited	Cells transformed with nucleic acid encoding ny-eso t cell receptors
GB0908613D0 (en) *	2009-05-20	2009-06-24	Immunocore Ltd	T Cell Reseptors
HRP20171164T1 (hr) *	2010-09-20	2017-10-20	Biontech Cell & Gene Therapies Gmbh	Antigen-specifični t stanični receptori i t stanični epitopi
EP2852613B1 (en) *	2012-05-22	2019-01-23	The United States of America, as represented by The Secretary, Department of Health and Human Services	Murine anti-ny-eso-1 t cell receptors
EP3404111A1 (en) *	2013-03-13	2018-11-21	Health Research, Inc.	Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
GB201522592D0 (en)	2015-12-22	2016-02-03	Immunocore Ltd	T cell receptors

2015
- 2015-12-22 GB GBGB1522592.3A patent/GB201522592D0/en not_active Ceased
2016
- 2016-12-22 EP EP16826144.4A patent/EP3394094B1/en active Active
- 2016-12-22 CN CN201680082629.2A patent/CN109476723B/zh not_active Expired - Fee Related
- 2016-12-22 US US16/065,047 patent/US11639374B2/en active Active
- 2016-12-22 DK DK16826144.4T patent/DK3394094T3/da active
- 2016-12-22 BR BR112018012794-9A patent/BR112018012794A2/pt not_active Application Discontinuation
- 2016-12-22 SG SG11201805268XA patent/SG11201805268XA/en unknown
- 2016-12-22 MX MX2018007621A patent/MX395153B/es unknown
- 2016-12-22 HR HRP20221021TT patent/HRP20221021T1/hr unknown
- 2016-12-22 PT PT168261444T patent/PT3394094T/pt unknown
- 2016-12-22 KR KR1020187020682A patent/KR20180090374A/ko not_active Ceased
- 2016-12-22 JP JP2018532590A patent/JP6985274B2/ja not_active Expired - Fee Related
- 2016-12-22 PL PL16826144.4T patent/PL3394094T3/pl unknown
- 2016-12-22 RS RS20220770A patent/RS63501B1/sr unknown
- 2016-12-22 WO PCT/GB2016/054032 patent/WO2017109496A1/en not_active Ceased
- 2016-12-22 MY MYPI2018001041A patent/MY196179A/en unknown
- 2016-12-22 ES ES16826144T patent/ES2923026T3/es active Active
- 2016-12-22 SI SI201631553T patent/SI3394094T1/sl unknown
- 2016-12-22 LT LTEPPCT/GB2016/054032T patent/LT3394094T/lt unknown
- 2016-12-22 CA CA3009400A patent/CA3009400A1/en active Pending
- 2016-12-22 AU AU2016375994A patent/AU2016375994B2/en not_active Ceased
- 2016-12-22 HU HUE16826144A patent/HUE059484T2/hu unknown
- 2016-12-22 SM SM20220336T patent/SMT202200336T1/it unknown
2018
- 2018-06-19 IL IL260151A patent/IL260151A/en unknown
2022
- 2022-08-24 CY CY20221100571T patent/CY1125508T1/el unknown

Also Published As

Publication number	Publication date
ES2923026T3 (es)	2022-09-22
MY196179A (en)	2023-03-20
AU2016375994B2 (en)	2021-08-19
US20190002523A1 (en)	2019-01-03
SI3394094T1 (sl)	2022-08-31
PT3394094T (pt)	2022-07-22
PL3394094T3 (pl)	2022-09-26
RU2018122795A (ru)	2020-01-23
HRP20221021T1 (hr)	2022-11-11
US11639374B2 (en)	2023-05-02
CN109476723A (zh)	2019-03-15
EP3394094B1 (en)	2022-05-25
DK3394094T3 (da)	2022-07-04
KR20180090374A (ko)	2018-08-10
GB201522592D0 (en)	2016-02-03
SMT202200336T1 (it)	2022-09-14
HUE059484T2 (hu)	2022-11-28
IL260151A (en)	2018-07-31
JP6985274B2 (ja)	2021-12-22
LT3394094T (lt)	2022-06-27
RU2018122795A3 (sr)	2020-05-29
EP3394094A1 (en)	2018-10-31
MX2018007621A (es)	2019-02-20
BR112018012794A2 (pt)	2018-12-04
RS63501B1 (sr)	2022-09-30
JP2019504026A (ja)	2019-02-14
AU2016375994A1 (en)	2018-07-05
MX395153B (es)	2025-03-24
CY1125508T1 (el)	2026-02-25
WO2017109496A1 (en)	2017-06-29
CA3009400A1 (en)	2017-06-29
CN109476723B (zh)	2022-01-28

Publication	Publication Date	Title
SG11201805268XA (en)	2018-07-30	T cell receptors specific for the ny-eso-1 tumor antigen-hla-a*02 complex
SG11201900955VA (en)	2019-03-28	T cell receptors and immune therapy using the same
SG11201808797XA (en)	2018-11-29	T cell receptors
SG11201900772YA (en)	2019-02-27	Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201407580YA (en)	2014-12-30	Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201807590SA (en)	2018-10-30	Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201805709RA (en)	2018-07-30	Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201806905UA (en)	2018-09-27	Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201900885VA (en)	2019-02-27	Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201810933QA (en)	2019-01-30	Anti-c5 antibodies and uses thereof
SG11201811003PA (en)	2019-01-30	Anti-pd-l1 antibodies and uses thereof
SG11201807279QA (en)	2018-09-27	Binding proteins and methods of use thereof
SG11201807868VA (en)	2018-10-30	Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201908238SA (en)	2019-10-30	Anti-c5 antibodies and uses thereof
SG11201901548SA (en)	2019-03-28	Anti-tim-3 antibodies and use thereof
SG11201805451TA (en)	2018-07-30	Immune effector cell therapies with enhanced efficacy
SG11201811432WA (en)	2019-03-28	Rna for cancer therapy
SG11201408780XA (en)	2015-01-29	Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201806150RA (en)	2018-08-30	Psma and cd3 bispecific t cell engaging antibody constructs
SG11201804839WA (en)	2018-07-30	Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201810023QA (en)	2018-12-28	Anti-tim-3 antibodies and methods of use thereof
SG11201900400QA (en)	2019-02-27	Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
SG11201803956UA (en)	2018-06-28	Anti-dr5 antibodies and methods of use thereof
SG11201806496SA (en)	2018-08-30	Antigen binding proteins that bind pd-l1
SG11201808762XA (en)	2018-11-29	Diagnostic methods for patient specific therapeutic decision making in cancer care